ArticleJournal of pediatric and adolescent gynecology2025
Effect of Transdermal Estrogen Therapy on Bone and Neurobehavioral Health in Youth with Premature Ovarian Insufficiency: A Case-Control Study.
Article in Journal of pediatric and adolescent gynecology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
STUDY
objectiveEstrogen replacement therapy (ERT) improves bone and neurocognitive health in adult women with premature ovarian insufficiency (POI). However, the response in adolescents is largely unknown. We aimed to assess the impact of transdermal estrogen replacement therapy on these outcomes in adolescents with POI.
methodsNine adolescents with idiopathic POI, naïve to ERT, and 9 controls with regular menses matched for age, race, and body mass index were recruited between 2018 and 2023 for a 24-month study. The primary bone health outcomes were changes in lumbar spine bone mineral density (BMD) Z-score and 3% distal radius trabecular volumetric BMD. The primary neurocognitive outcomes were quality of life (CHQ-87 survey) and memory (ChAMP).
resultsAdolescents with POI experienced significant increases in BMD Z-scores at all dual-energy x-ray absorptiometry skeletal sites (lumbar spine ∆ +0.68, total hip ∆ +0.37, femoral neck ∆ +0.56, total body less head ∆ +0.82, all P < .05). Control participants exhibited an increase in BMD Z-score at the total body less head (∆ 0.43, P = .034) with no significant change at other skeletal sites. There were no significant changes from baseline to 24 months in peripheral quantitative computed tomography measures. Total memory index significantly increased in both groups from baseline to 24 months (controls ∆ +17.2, cases ∆ +24.6, P = .041 and .001, respectively), but there was no difference between groups. There were no other significant differences in neurocognitive outcomes among or between groups.
conclusionCentral BMD increased in adolescents with idiopathic POI in response to transdermal estrogen replacement therapy, but peripheral BMD measures were unchanged. The impact on neurocognitive outcomes in these adolescents remains uncertain.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.